The analysis included laboratory results and questionnaire responses from 264 randomly selected adults aged 19 to 60 years, with a mean age of 41.19 years. The sample comprised 109 men and 155 women. By body mass index, 72 participants had normal weight, 65 were overweight and 127 had obesity. People with conditions that could affect comparability, including heart failure, kidney disease, liver cirrhosis, thyroid disorders and certain other chronic illnesses, were excluded.

Participants were grouped by serum 25(OH)D status as sufficient at 50 nmol/L or higher, insufficient at 25–49.9 nmol/L, or deficient below 25 nmol/L. Investigators measured height, weight, waist circumference and blood pressure. Body composition was assessed by bioelectrical impedance analysis and dual-energy X-ray absorptiometry. A single morning blood sample collected after a 12-hour overnight fast was used to measure 25(OH)D, glucose, insulin, triglycerides, total cholesterol, HDL-C, LDL-C and high-sensitivity C-reactive protein. HOMA-IR, an index of insulin resistance, was calculated from fasting glucose and fasting insulin rather than measured directly as a blood marker.

Vitamin D status was significantly associated with BMI category (p < 0.001). Mean serum 25(OH)D concentrations declined across BMI categories, from 48.80 nmol/L among normal-weight participants to 22.20 nmol/L among those with class III obesity. Vitamin D deficiency was present in 54.0% of participants with class II–III obesity, compared with 18.1% of those with normal weight. In the class II–III obesity group, 10.0% had sufficient 25(OH)D and no participants had the optimal status reported in the study.

Greater vitamin D deficiency was associated with higher BMI, waist-to-height ratio, percentage body fat and visceral fat mass in both men and women. Across the full sample, the strongest inverse correlations between 25(OH)D and body-composition measures involved fat mass in kilograms and percentage, fat mass index and waist-to-height ratio. Their Spearman coefficients were −0.339, −0.339, −0.343 and −0.307, respectively. Body weight, waist circumference and BMI also had significant inverse correlations with serum 25(OH)D.

Serum 25(OH)D was inversely associated with several cardiometabolic markers. Across the full group, significant correlations were observed for triglycerides, HOMA-IR, high-sensitivity C-reactive protein, fasting insulin and the ratio of total cholesterol to HDL-C. Among participants with class II or class III obesity, 25(OH)D was also associated with triglycerides, the LDL-C-to-HDL-C ratio, HOMA-IR, high-sensitivity C-reactive protein and glucose measured 120 minutes after an oral glucose tolerance test. The study reported no significant correlations between 25(OH)D and the assessed biochemical parameters in the overweight or class I obesity groups.

Multiple linear regression treated the measured serum 25(OH)D concentration as the outcome. In the full sample, the TC-to-HDL-C and LDL-C-to-HDL-C ratios and percentage body fat were among the strongest statistical predictors. Subgroup models identified fasting glucose and BMI in men; percentage body fat, body water content and waist circumference in women; fasting insulin and waist-to-height ratio among normal-weight participants; and BMI and fasting insulin among participants with excess BMI. These models describe associations within the study sample and do not establish predictive performance in other populations.

Questionnaire data showed differences in reported diseases across vitamin D groups. Cardiovascular disease was reported by 15.9% of participants with deficiency, compared with 6.6% of those with insufficiency and 7.1% of those with sufficient status (p < 0.01). Diabetes was reported by 8.0%, 3.8% and 4.3%, respectively, while overweight or obesity was reported by 70.5%, 60.4% and 48.6% (p < 0.001 for each comparison). Elevated blood pressure was reported by 36.4% of deficient participants and 30.0% of those with sufficient concentrations. Depression was also more frequently reported among deficient participants, 25.0% versus 10.0% (p < 0.001).

The findings are limited by the cross-sectional design, the sample of 264 adults and the use of self-reported questionnaires for disease prevalence. Associations among vitamin D status, body composition and cardiometabolic measures cannot be interpreted as causal effects. The study did not test vitamin D supplementation or any cardiovascular treatment. Its results instead document measured relationships in this population, including lower 25(OH)D concentrations at higher BMI and differences in reported cardiovascular and metabolic conditions across vitamin D status groups.

Subject of Research: Associations of vitamin D status and body mass index with cardiometabolic risk markers and reported cardiovascular disease in adults

Article Title: Association of vitamin D status and body mass index with cardiometabolic risk and cardiovascular disease in adults

Article References: Nikolova, M., Alakidi, A., Tafradjiiska-Hadjiolova, R., Petkova, V., & Agovska, A. (2026). Association of vitamin D status and body mass index with cardiometabolic risk and cardiovascular disease in adults. Pharmacia, 73, Article e198293. https://doi.org/10.3897/pharmacia.73.e198293

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e198293

Keywords: vitamin D status, 25-hydroxyvitamin D, body mass index, adiposity, cardiometabolic risk, cardiovascular disease, insulin resistance, inflammation, cross-sectional study, Association, vitamin, status

Of the 922 adults, 918 contributed to latent class analysis based on 18 indicators covering physical conditions, mental health conditions, and behavioural risks. Adverse childhood experiences were represented in two ways: a standardised version of an archived 13-domain count and three re-estimated adversity classes. For the count measure, unobserved domains were treated as unendorsed when at least one domain had been observed; otherwise, the count was treated as missing. Multinomial models used 200 pseudo-class draws to propagate uncertainty in adult-profile assignments, while the adversity-class models also propagated uncertainty in the adversity classifications. The abstract reports both unadjusted and age-, gender-, and nationality-adjusted relative risk ratios.

Each one-standard-deviation increase in the childhood-adversity count had its strongest association with membership in the Mental health and multi-burden profile rather than the Low burden profile. The unadjusted relative risk ratio was 2.94 (95% confidence interval, 2.38–3.63), and the adjusted estimate was 2.86 (2.30–3.55). Smaller adjusted associations were reported for Substance/prescription vulnerability, at 1.51 (1.15–2.00), and Cardiometabolic burden, at 1.39 (1.03–1.86); the corresponding unadjusted confidence intervals included 1, making these smaller associations sensitive to model specification.

In the adversity-class models, Household/interpersonal adversity was associated with the Mental health and multi-burden profile relative to Low adversity, with an adjusted relative risk ratio of 7.21 (4.12–12.60). Polyvictimisation/high violence was associated with Mental health and multi-burden at 21.31 (8.74–51.95) and Cardiometabolic burden at 3.92 (1.21–12.72), although the abstract notes that these estimates were imprecise. The findings show associations in a convenience sample and do not establish that childhood adversity caused profile membership. The reliance on retrospective reports, the sample setting and the imprecision of some class-based estimates limit how broadly the results can be generalised or interpreted.

Subject of Research: Associations between retrospectively reported childhood adversity and adult health and behavioural-risk profiles in an Abu Dhabi convenience sample

Article Title: Patterns of adversity, patterns of burden: a person-centred analysis of adult health and behavioural-risk profiles in Abu Dhabi

Article References: Murphy, A., Horen, N., Long, T., Edgemon, T. G., Elbarazi, I., England, D., & Arafat, C. (2026). Patterns of adversity, patterns of burden: a person-centred analysis of adult health and behavioural-risk profiles in Abu Dhabi. BMC Public Health. https://doi.org/10.1186/s12889-026-29611-3

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29611-3

Keywords: adverse childhood experiences, Abu Dhabi, adult health profiles, latent class analysis, mental health, behavioural risks, cardiometabolic burden, health inequality, retrospective reporting, BMC Public Health, Patterns, adversity

Aortic stenosis has long been viewed as a mechanical problem: calcium accumulates on the aortic valve over decades, the valve opening narrows, and the heart struggles to push blood through. But the new study reinforces a very different picture that has been emerging over the past two decades. Degenerative aortic stenosis is an actively inflammatory process, sharing many of the same cellular and molecular players that drive atherosclerosis, including oxidized lipids, monocytes, T lymphocytes, and pro-inflammatory signaling cascades. The authors frame this within the concept of inflammaging, the chronic, low-grade, sterile inflammation that rises with age and feeds a vicious cycle accelerating structural cardiovascular changes, cardiometabolic disease, and valvular calcification simultaneously.

The RCII is designed to quantify precisely that intersection. It is calculated as the product of remnant cholesterol, the cholesterol carried in triglyceride-rich lipoprotein particles, and high-sensitivity C-reactive protein, divided by ten. Remnant cholesterol is obtained by subtracting HDL and LDL cholesterol from total cholesterol, making it derivable from any standard lipid panel. Remnant particles are considered highly atherogenic because they infiltrate the arterial intima, activate vascular and immune cells, and promote endothelial dysfunction and cholesterol deposition. C-reactive protein, meanwhile, is a hallmark of inflammaging, activating the complement system, recruiting macrophages to arterial walls, and promoting cytokine production and plaque vulnerability. Multiplying the two creates an index that reflects the joint burden of lipid-driven and inflammation-driven vascular injury.

The study population consisted of elderly patients, averaging 83.5 years of age and predominantly female, referred to the outpatient clinic of the Ospedale del Cuore in Massa, Italy, between March 2016 and March 2020. All had severe aortic stenosis with preserved left ventricular systolic function and underwent a multidisciplinary heart team evaluation including clinical, surgical, laboratory, and multidimensional geriatric assessment. The cohort carried a heavy cardiometabolic burden: 88 percent had hypertension, 74 percent had dyslipidemia, and 36 percent had type 2 diabetes. Frailty was assessed using the Fried phenotype criteria, and every patient was classified as at least pre-frail. Patients with acute heart failure, hemodynamic shock, or active infection were excluded to avoid distorting the inflammatory biomarkers under study.

The correlation analysis produced a strikingly coherent pattern. RCII levels correlated most strongly with interleukin-6, a central pro-inflammatory cytokine, with a correlation coefficient of 0.6, and also showed significant positive associations with neutrophils, the neutrophil-to-lymphocyte ratio, monocytes, platelets, erythrocyte sedimentation rate, and fibrinogen. Positive correlations, albeit weaker, emerged with glucose and creatinine, pointing toward disturbed glucose metabolism and renal involvement. The index also correlated with vascular endothelial growth factor, a mediator of the angiogenesis that occurs within calcified valves, and with frailty scores, suggesting that RCII may capture a multisystem vulnerability rather than a single disease process. Inverse correlations appeared with albumin, which typically falls during inflammatory states, and with HDL cholesterol, indicating that a high RCII reflects an unfavorable metabolic profile.

The survival findings carried the study’s most consequential implication. Over a mean follow-up of 19 months, ten cardiovascular deaths occurred. Kaplan-Meier analysis showed significantly worse survival among patients whose RCII exceeded the 75th percentile, a threshold of 17.6. In an exploratory multivariable Cox regression, higher RCII remained associated with cardiovascular mortality with a hazard ratio of 3.5, alongside elevated neutrophil counts, which showed a hazard ratio of 5.1. The authors are careful to stress, however, that the confidence interval for the RCII estimate was wide, spanning from 1.0 to 12.0, and that the small number of deaths limits statistical power. They explicitly describe the association as exploratory and hypothesis-generating rather than evidence of an established independent prognostic role.

Beneath the statistical associations lies a plausible molecular mechanism centered on the NLRP3 inflammasome, a multiprotein complex that, when activated, triggers caspase-1 and drives the release of pro-inflammatory cytokines such as interleukin-6, prompting the liver to produce C-reactive protein and fibrinogen. Oxidized LDL particles are important regulators of this inflammasome, making it a candidate link between the cholesterol pathway and vascular inflammation. In the context of aortic stenosis, NLRP3 activation promotes the transformation of valvular interstitial cells into bone-like cells, driving osteogenic calcification, and experimental studies have shown that blocking the inflammasome can reduce or reverse valve calcification in animal models. The same pathway has been implicated in frailty, sarcopenia, and cognitive decline, which may explain why a biomarker combining lipid and inflammatory signals tracked so closely with frailty in this cohort.

This mechanistic overlap also opens a therapeutic horizon. Drugs that target the NLRP3 inflammasome or its downstream interleukin-1 signaling, including anakinra, colchicine, canakinumab, and rilonacept, could in principle counteract inflammaging, atherosclerosis, and valvular calcification simultaneously. The authors also note that RCII is actionable in a broader sense, since both of its components can be modified by lipid-lowering and anti-inflammatory strategies or lifestyle changes. Yet they caution that therapies effective in atherosclerosis have not consistently shown benefit in aortic stenosis, and no pharmacological treatment currently exists to prevent or delay the progression of calcific valve disease, which is why sensitive biomarkers capable of detecting early, still-modifiable disease stages are so urgently needed.

The study has important limitations that the authors confront directly. It was retrospective, IL-6 and VEGF were measured in only 23 of the 103 patients, and the low number of cardiovascular deaths raises the risk of model instability and overfitting in the multivariable analysis. The study also cannot establish whether RCII adds predictive information beyond established clinical variables such as age, frailty, diabetes, renal function, BNP, aortic valve gradient, prior myocardial infarction, and treatment strategy. Before any clinical adoption, the authors call for external validation, standardized thresholds, serial measurements, and head-to-head comparison with established risk prediction models.

Even with those caveats, the appeal of RCII is hard to ignore. It requires no new technology, no specialized assay, and no additional blood draw, being computable from a routine lipid panel and a standard C-reactive protein measurement. Prior studies have linked the index to stroke risk, all-cause and cardiovascular mortality, metabolic syndrome, diabetes incidence, and short-term mortality in acute decompensated heart failure, with some large population analyses finding nearly sevenfold higher odds of metabolic syndrome in the highest RCII quartile. If larger prospective studies confirm the Italian team’s preliminary signal, this low-cost index could help clinicians identify which elderly patients with aortic stenosis carry the greatest hidden inflammatory-metabolic risk, opening a window for earlier, personalized prevention in a population where every month of modifiable risk matters.

Subject of Research: The remnant cholesterol inflammatory index as a predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis

Article Title: Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis

Article References: Mazzone, A., Gaggini, M., Foffa, I., Del Turco, S., Minichilli, F., Berti, S., & Vassalle, C. (2026). Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis. Frontiers in Endocrinology, 17, Article 1894558. https://doi.org/10.3389/fendo.2026.1894558

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1894558

Keywords: aortic stenosis, remnant cholesterol inflammatory index, inflammaging, cardiovascular mortality, C-reactive protein, frailty, NLRP3 inflammasome, cardiometabolic risk, elderly patients, biomarker, interleukin-6, valve calcification

The research team assembled a retrospective cohort of 289 children between the ages of six and twelve who had been diagnosed with obesity at their hospital between March 2021 and March 2024. Rather than randomizing participants, the investigators compared two real-world pathways. One group of 162 children was enrolled in a family-centered comprehensive lifestyle intervention, a twelve-month multidisciplinary program that wove together dietary counseling, physical activity guidance, behavioral support, and medical monitoring, all delivered with the household as the unit of change. The remaining 127 children received routine guidance, the standard health education that most pediatric clinics dispense: advice sheets, brief counseling sessions, and periodic weigh-ins.

What distinguishes this study from the crowded field of pediatric weight-loss trials is the sheer breadth of its measurement battery. At baseline and again at the twelve-month follow-up, the researchers captured anthropometric data, full body composition, blood pressure, lipid profiles, glucose metabolism indices, inflammatory markers, liver function, uric acid, cardiovascular structure, and health-related quality of life. That last category, assessed with the Pediatric Quality of Life Inventory, is often an afterthought in cardiometabolic research. Here it was treated as a primary outcome, a deliberate choice that reflects a growing recognition in pediatric medicine that a child’s subjective wellbeing is not separable from their metabolic status.

The numbers, when they arrived, were strikingly consistent. Children in the family-centered program showed an adjusted mean difference in body mass index of minus 1.23 compared with the routine guidance group, with a 95 percent confidence interval running from minus 1.80 to minus 0.66. Waist circumference, a proxy for visceral adiposity that many researchers consider more prognostically meaningful than BMI itself, dropped by an adjusted 4.13 centimeters on average. Body fat percentage fell by 2.61 points. Each of these differences was statistically robust, with adjusted p-values below 0.001, and each moved in the direction that a decade of pediatric obesity literature would predict only from sustained, genuine behavioral change rather than measurement noise or regression to the mean.

But the story does not end at the tape measure. Systolic blood pressure in the intervention group was an adjusted 4.23 millimeters of mercury lower than in the comparison group. The homeostasis model assessment of insulin resistance, the workhorse index known as HOMA-IR that captures how hard the pancreas is working to keep blood glucose in check, improved by an adjusted 0.46 units. High-sensitivity C-reactive protein, the systemic inflammation marker that cardiologists track as a harbinger of atherosclerotic disease, fell by 0.57 milligrams per liter. Uric acid declined, lipid profiles shifted favorably, and the children reported a meaningfully better quality of life, with total PedsQL scores rising by an adjusted 4.73 points.

Perhaps most remarkable are the structural findings. The researchers documented improvements in cardiac structure and a reduction in carotid intima-media thickness, the thickness of the innermost layers of the carotid artery wall that ultrasound can measure noninvasively. In adult medicine, carotid intima-media thickness is treated as a window into early atherosclerosis, a disease process that typically takes decades to become clinically manifest. Finding that a twelve-month lifestyle intervention was associated with measurable favorable change in school-aged children suggests that the vascular consequences of childhood obesity are not merely a future risk to be managed but an active, ongoing process that responds to intervention in near real time. All of these secondary outcomes reached statistical significance at p below 0.05.

The mechanism, the authors argue, is baked into the design of the intervention itself. A six-year-old does not shop for groceries, plan meals, or decide whether the evening is spent on a screen or a soccer field. Conventional pediatric obesity counseling that addresses the child in isolation asks the least empowered member of the household to engineer her own environment, which is a bit like prescribing a diet to someone else’s pantry. A family-centered model instead treats the home as the therapeutic unit, aligning parents, siblings, and caregivers around shared changes in food, activity, and routine. The multidisciplinary structure, drawing on pediatric, endocrine, nutritional, and behavioral expertise over a full year, provides the scaffolding that single-visit advice cannot.

The quality-of-life result deserves particular attention because it complicates a persistent fear in pediatric weight management: that intensive intervention damages children’s self-image. In this cohort, the opposite occurred. Children whose families went through the program together reported better overall health-related quality of life, not worse, with the adjusted difference of 4.73 PedsQL points reaching significance at p equal to 0.002. The implication is that when lifestyle change is framed as a household project rather than a child’s personal failure, the psychological burden of intervention may transform into psychological benefit.

Honest caveats temper the enthusiasm, and the authors are careful to supply them. This was a retrospective, non-randomized study, which means families were not assigned to their groups by chance. It is entirely possible that households willing and able to commit to a twelve-month multidisciplinary program differed systematically from those that received routine guidance, in motivation, resources, health literacy, or baseline stability, and that these differences, rather than the intervention itself, drove part of the observed benefit. The authors state plainly that the findings should be interpreted as hypothesis-generating associations rather than causal effects. Adjusted analyses can narrow the gap between groups statistically, but they cannot manufacture the equivalence that randomization provides.

Even with that caution, the study lands at a consequential moment. Childhood obesity continues to climb globally, and the pharmacological options now arriving for adults are raising uncomfortable questions about lifelong medication in growing bodies. Against that backdrop, evidence that a structured, family-centered, non-pharmacological program can shift not just weight but insulin resistance, systemic inflammation, blood pressure, arterial wall thickness, and a child’s own reported wellbeing is a signal worth taking seriously. The next step, which this study’s authors implicitly invite, is the randomized trial that can separate the program’s effect from the families who choose it. If the associations hold, the prescription for pediatric obesity may turn out to be written not for the child at all, but for everyone who shares her dinner table.

Subject of Research: Family-centered lifestyle intervention for childhood obesity and cardiometabolic health

Article Title: Long-term effects of a family-centered comprehensive lifestyle intervention on body composition and cardiometabolic indicators in school-aged obese children aged 6–12 years

Article References: Lv, F., & Wang, Y. (2026). Long-term effects of a family-centered comprehensive lifestyle intervention on body composition and cardiometabolic indicators in school-aged obese children aged 6–12 years. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07616-6

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07616-6

Keywords: childhood obesity, family-centered care, pediatric health, cardiometabolic risk, body composition, insulin resistance, blood pressure, inflammation, quality of life, lifestyle intervention, retrospective study, BMC Pediatrics

The scale of the analysis lends the observation considerable weight. Researchers examined the prevalence of four neurodivergent conditions, namely ADHD, autism, dyslexia and dyspraxia, among approximately 4.2 million individuals newly diagnosed with type 2 diabetes in the TriNetX US collaborative network between March 2006 and March 2026. To account for demographic differences that might otherwise distort the comparison, each ten-year age band of people with diabetes was matched by age, year of birth, sex, ethnicity and race to individuals without the condition, drawn from a pool of 17.1 million. In total, 3.4 million matched pairs aged younger than eighty years entered the final analysis. This matching strategy is important because neurodivergent conditions are not distributed evenly across the population, and differences in sex, ethnicity or birth cohort could easily masquerade as a diabetes link if left unadjusted.

The headline numbers are most dramatic at the youngest ages. Among people diagnosed with type 2 diabetes before their twentieth birthday, ADHD reached a prevalence of 14.4 percent, compared with 6.9 percent among matched individuals of similar age without diabetes, a difference of just over twofold. Autism showed an even steeper gap, at 5.72 percent versus 1.79 percent, meaning the condition was more than three times as prevalent in the young diabetes group. Dyslexia and dyspraxia were also more common among younger people overall, and across all ages people with type 2 diabetes were roughly twice as likely to have dyslexia as those without, although this difference did not appear to follow any obvious pattern with age at diagnosis. Taken together, the data suggest that as many as one in seven young people with early-onset type 2 diabetes may also be living with ADHD, and roughly one in twenty with autism.

Age emerged as a critical variable in the analysis. Across both groups, the prevalence of neurodiversity was highest at younger ages and declined rapidly with increasing age, becoming extremely low beyond the age of forty. The gap between those with and without diabetes narrowed as age at diagnosis rose. ADHD, for example, was around 1.4 times more prevalent among people diagnosed with type 2 diabetes at seventy to seventy-nine years, at 0.25 percent versus 0.18 percent, compared with the more than twofold difference seen in the under-twenties. Autism followed the same trajectory, being 1.24 times higher in the oldest diagnostic group, although prevalence was so low in that age band, less than 0.01 percent with or without diabetes, that the comparison is difficult to interpret. The concentration of the association in youth is precisely what makes the findings clinically consequential, since early-onset diabetes is the fastest-growing and most vulnerable segment of the type 2 diabetes population.

The clinical stakes are considerable. Early-onset type 2 diabetes is associated with poorer health outcomes than later-onset disease, partly because a diagnosis at a younger age means a longer lifetime exposure to elevated blood glucose and its vascular consequences, raising the risk of serious complications and early death. Managing the condition demands sustained engagement with healthcare services, careful self-monitoring, medication adherence and lifestyle modification, all of which can be complicated by stigma and the competing demands of early adulthood, such as education, employment and establishing independence. For neurodivergent individuals, these demands can be compounded further. Busy clinics, unfamiliar environments, sensory pressures and communication barriers may make routine diabetes care genuinely difficult to navigate, potentially widening existing inequalities in outcomes.

Lead author Dr Jonathan Goldney, of the University of Leicester Diabetes Research Centre and the NIHR Biomedical Research Centre in Leicester, argued that health services are not currently equipped for this overlap. Health systems, he said, are failing to fully meet the needs of people living with both early-onset type 2 diabetes and neurodiversity, both of which are linked to poorer health outcomes. He noted that neurodivergent people and those with early-onset type 2 diabetes are likely to face unique challenges when navigating busy healthcare environments, communicating with healthcare professionals, and managing their diabetes. In his view, providing healthcare for type 2 diabetes in a way that suits neurodivergent individuals is critical to making care more accessible for everyone, particularly as diagnoses are increasingly being made earlier in life. The authors emphasise that the point is not that most neurodivergent people will develop diabetes, but that services for early-onset disease should be planned with neurodiversity in mind.

Why might neurodivergent conditions and early-onset type 2 diabetes travel together? The authors speculate that several mechanisms could contribute. Lower levels of physical activity, difficulties with sleep, the metabolic effects of certain medications, higher rates of mental health conditions and barriers to accessing healthcare could each plausibly raise cardiometabolic risk over time. Factors operating earlier in life may also matter. Maternal diabetes during pregnancy has previously been associated with altered neurodevelopmental outcomes in children as well as with later cardiometabolic risk, suggesting that shared developmental or genetic pathways could underlie part of the association. Shared genetic architecture between neurodevelopmental conditions and metabolic traits is an active area of research, and the present study was not designed to distinguish between behavioural, environmental, iatrogenic and biological explanations. Disentangling these threads is precisely what the authors say future work should address.

The observational design imposes important caveats. A study of this kind can identify associations but cannot establish cause and effect, and the influence of factors that were not measured cannot be ruled out. The analysis relied on anonymised hospital records, which may be prone to coding errors and were not collected specifically for research purposes. There is also a detection issue: people with neurodivergent conditions tend to have more frequent contact with healthcare professionals, which could increase the opportunities for a type 2 diabetes diagnosis to be made and recorded, inflating the apparent association. Furthermore, because the study only included people who had attended hospital, the sample may not be fully representative of the wider population and could exclude healthier individuals, a limitation that may have affected the prevalence estimates particularly among younger people without diabetes, where the comparison figures were very low.

Despite these limitations, the sheer size of the matched cohort makes the central signal difficult to dismiss, and the authors are clear about what should happen next. Future studies, they say, should explore the factors underlying the association between neurodivergent conditions and type 2 diabetes, and should test whether diabetes care that explicitly takes neurodiversity into account can improve health outcomes. Practical implications could include longer or more flexible appointments, adapted communication styles, sensory-considered clinic environments and closer collaboration between diabetes teams and neurodevelopmental services. The authors declare no conflicts of interest. As early-onset type 2 diabetes continues to climb among adolescents and young adults, the study suggests that recognising and accommodating neurodiversity will be an essential part of building diabetes services that work for the patients who need them most.

Subject of Research: The association between neurodivergent conditions and early-onset type 2 diabetes in a large matched cohort study

Article Title: High prevalence of neurodiversity among young people diagnosed with type 2 diabetes, suggests study of over 6 million people

Article References: High prevalence of neurodiversity among young people diagnosed with type 2 diabetes, suggests study of over 6 million people. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, neurodiversity, ADHD, autism, early-onset diabetes, EASD, TriNetX, dyslexia, dyspraxia, health services, observational study, cardiometabolic risk

CagriSema represents a convergence of two hormonal pathways that have reshaped metabolic medicine over the past decade. Semaglutide, already established as a blockbuster therapy for both diabetes and obesity, mimics glucagon-like peptide-1 to enhance insulin secretion, suppress glucagon release, and slow gastric emptying. Cagrilintide, by contrast, is a long-acting analogue of amylin, a peptide co-secreted with insulin from pancreatic beta cells that contributes to satiety signaling and post-meal glucose regulation. By pairing these two mechanisms in a single weekly injection, CagriSema is designed to exploit complementary appetite and glycemic pathways simultaneously, an approach that has generated considerable excitement about whether combination therapy could outperform either component alone.

To quantify that promise rigorously, the investigators searched PubMed, Embase via Elsevier, the Cochrane Library, and ClinicalTrials.gov through June 2026, identifying randomized controlled trials that compared CagriSema against placebo, semaglutide, or cagrilintide. They applied random-effects meta-analytic models, calculating mean differences for continuous outcomes such as HbA1c and body weight, and risk ratios for dichotomous outcomes such as adverse events and treatment discontinuation, each with 95 percent confidence intervals. Methodological quality was evaluated using the Cochrane Risk of Bias 2 tool, and the certainty of evidence was graded with the GRADE framework, yielding assessments that ranged from low to high across the reported outcomes. That spectrum of certainty is itself informative, signaling where the evidence base is robust and where longer-term data remain necessary.

The glycemic results were striking at both doses tested. At the 2.4 mg dose, CagriSema reduced HbA1c by a mean difference of 1.01 percentage points compared with controls, with a confidence interval spanning from 1.44 down to 0.57 percentage points, and lowered fasting plasma glucose by 1.41 mmol/L. The 1 mg dose, though slightly less potent on average, still delivered a clinically meaningful HbA1c reduction of 0.99 percentage points and a fasting plasma glucose decline of 1.04 mmol/L. For context, a reduction approaching one percentage point in HbA1c is comparable to or exceeds the effect seen with many established glucose-lowering agents, and achieving it with a single weekly injection would represent a significant therapeutic advance for patients whose glycemic targets remain out of reach on current regimens.

Where CagriSema truly distinguished itself was in body weight and cardiometabolic parameters. The 2.4 mg dose produced a mean body weight reduction of 8.31 percent, with confidence intervals indicating the true effect could range from 10.58 down to 6.04 percent, alongside a 7.32 cm reduction in waist circumference and a 4.30 mmHg drop in systolic blood pressure. Remarkably, the 1 mg dose showed a comparable weight effect of 8.76 percent, with wider uncertainty reflecting fewer pooled participants at that dose level, plus reductions of 5.66 cm in waist circumference and 4.73 mmHg in systolic blood pressure. The near-parity in weight loss between the two doses raises intriguing pharmacological questions about whether the amylin component drives much of the weight effect and whether dose escalation primarily refines glycemic control rather than amplifying weight reduction.

Safety findings added important nuance to the efficacy story. Serious adverse events did not differ significantly between CagriSema and comparators at either dose, a reassuring signal that the combination does not appear to elevate major safety risks in the trial populations studied. However, gastrointestinal adverse events and treatment discontinuation were both more frequent with the 2.4 mg dose, consistent with the dose-dependent tolerability profile seen across the incretin-based drug class. The 1 mg dose produced a smaller increase in gastrointestinal side effects and, notably, did not significantly increase discontinuation rates compared with control groups. This dose-response asymmetry suggests that a substantial fraction of patients could capture most of the metabolic benefit at the lower dose while avoiding the tolerability ceiling that often forces dose interruption.

The GRADE certainty ratings, spanning low to high across outcomes, underscore both the strength and the limitations of the current evidence. High-certainty findings provide confidence in the core glycemic and weight effects, while lower-certainty outcomes reflect the inherent constraints of pooling a limited number of trials with heterogeneous designs, durations, and comparator arms. The authors themselves emphasize that long-term randomized studies are needed to confirm the safety and durability of CagriSema’s effects, a caveat that matters enormously for a therapy intended to be used chronically in a condition that requires lifelong management.

The clinical implications of this dose-specific analysis are considerable. For patients with type 2 diabetes whose primary challenge is glycemic control, the 1 mg dose appears to offer nearly the full HbA1c benefit with a more favorable tolerability profile. For those whose treatment goals prioritize substantial weight reduction and cardiovascular risk factor improvement, the 2.4 mg dose delivers greater effects on waist circumference and comparable blood pressure benefits, at the cost of more gastrointestinal events and higher discontinuation. This kind of dose-stratified evidence is precisely what prescribers need as incretin-based combination therapies move from trial protocols into routine endocrinology practice, where individualized titration decisions carry real consequences for adherence and outcomes.

Looking ahead, the CagriSema story sits at the frontier of a broader shift in metabolic medicine, where multi-agonist molecules are being engineered to replicate the coordinated hormonal responses that follow bariatric surgery. The meta-analysis confirms that combining amylin and GLP-1 signaling produces additive benefits on glucose and weight without a proportional increase in serious adverse events, validating the dual-pathway hypothesis in a large pooled population. As longer-duration trials mature and head-to-head comparisons against established therapies accumulate, the field will gain clarity on where CagriSema fits within the therapeutic arsenal. For now, this analysis provides the most comprehensive dose-specific evidence synthesis to date, and it suggests that for millions of people with type 2 diabetes, a single weekly injection targeting two hormonal systems simultaneously may soon offer a level of glycemic and weight control previously achievable only through surgical intervention.

Subject of Research: Dose-specific efficacy and safety of the cagrilintide-semaglutide combination CagriSema in type 2 diabetes

Article Title: Dose-specific efficacy and safety of cagrisema in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Article References: Khan, B. W., Khattak, M. H., Yahya, M., Khan, M. M., Qazi, T. I., Yar, S., Khan, M. M., Amjad, M. M., Bibi, H., Muneeb, M., Khan, S., Muiz, A., Fayyaz, M. M. N., Malik, A. A., Arify, J., Khan, U. Z., & Batool, A. (2026). Dose-specific efficacy and safety of cagrisema in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02657-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02657-5

Keywords: CagriSema, cagrilintide, semaglutide, type 2 diabetes, meta-analysis, randomized controlled trials, HbA1c, weight loss, GLP-1 receptor agonist, amylin analogue, cardiometabolic risk, drug safety

The research team, which included investigators from Erasmus MC in Rotterdam, the Institute of Agrochemistry and Food Technology in Valencia, and Helmholtz Munich, among other institutions, set out to answer a deceptively simple question: which exposures occurring before conception, during pregnancy and birth, and in infancy up to two years of age are associated with cardiometabolic outcomes in later childhood and adolescence? The outcomes they examined were the five canonical precursors of adult cardiovascular disease: glucose intolerance, dyslipidemia, hypertension, metabolic syndrome, and type 2 diabetes. The review was prospectively registered with PROSPERO under registration number CRD42022355152, and the authors followed PRISMA reporting guidelines to ensure methodological transparency. The 70 studies that met the inclusion criteria comprised 65 longitudinal observational studies, four case-control studies, and one randomized controlled trial, a distribution that reflects the ethical and practical constraints of studying developmental exposures in human populations.

What distinguishes this meta-analysis from previous efforts is its rigorous handling of statistical dependency. Because many large birth cohorts contribute multiple overlapping publications, naive pooling can artificially inflate the precision of an estimate by counting the same children more than once. The authors addressed this by revising their meta-analyses to retain only one independent estimate per source cohort, a correction that materially changed the precision of the pooled results. The gestational diabetes finding survived this scrutiny with remarkably low heterogeneity, an I-squared value of just 12.7 percent, indicating that the underlying studies were unusually consistent in the direction and magnitude of the association. The team also classified any meta-analysis based on fewer than five independent studies as exploratory, a conservative decision that separates robust conclusions from preliminary signals and provides a template for how future reviews in this field should handle sparse evidence.

Gestational diabetes mellitus emerged as the most consequential early-life exposure in the entire analysis. It was positively associated with every cardiometabolic risk outcome examined, with glucose intolerance being the most frequently reported. This finding carries particular biological plausibility. During a pregnancy complicated by gestational diabetes, the fetus is exposed to elevated maternal glucose, which crosses the placenta and stimulates fetal insulin production. Chronic hyperinsulinemia in the developing fetus can alter pancreatic beta-cell function, adipose tissue development, and hypothalamic programming of appetite and metabolism. Animal models have shown that such developmental exposures can permanently reprogram metabolic homeostasis, a phenomenon known as metabolic imprinting or fetal programming. The human evidence now assembled in this meta-analysis suggests that the same mechanisms operate in real-world populations, producing measurable cardiometabolic consequences that persist into adolescence.

Maternal body mass index during pregnancy was another exposure with broad reach across the cardiometabolic spectrum. Higher maternal pregnancy BMI was positively associated with glucose intolerance, dyslipidemia, hypertension, and metabolic syndrome in offspring. The biological pathways here are multifaceted. Maternal obesity is accompanied by elevated circulating free fatty acids, inflammatory cytokines, and leptin, all of which can cross the placenta and influence fetal development. Maternal insulin resistance, a hallmark of obesity, can also alter nutrient delivery to the fetus and modify the intrauterine metabolic environment. The consistency of the association across four distinct cardiometabolic outcomes suggests that maternal obesity acts through a general developmental perturbation rather than through a single organ-specific pathway, a conclusion that aligns with the developmental origins of health and disease framework that has gained prominence over the past three decades.

The analysis also examined birth characteristics and found that being born small for gestational age was associated with higher odds of hypertension in later childhood and adolescence, though this finding was classified as exploratory because it was based on fewer than five independent studies. The corresponding exploratory analysis for preterm birth and elevated systolic blood pressure did not reach statistical significance and is presented for methodological illustration only. The authors also found that low or high birth weight, and being born large for gestational age, were associated with cardiometabolic outcomes in childhood and adolescence. The link between restricted fetal growth and later hypertension is biologically coherent. Fetuses that experience intrauterine growth restriction often develop a preferential blood flow pattern that shunts oxygen and nutrients toward the brain at the expense of other organs, including the kidneys. Reduced nephron number in the developing kidney is a well-established mechanism for later hypertension, because a smaller nephron complement increases sodium retention and raises blood pressure throughout life.

Infant BMI and weight changes during the first two years of life were positively associated with dyslipidemia, hypertension, and metabolic syndrome in later childhood and adolescence. This finding is notable because it extends the window of cardiometabolic vulnerability beyond the intrauterine period and into postnatal development. Rapid weight gain in infancy, sometimes called catch-up growth, has been proposed as a mechanism that can alter body composition, insulin sensitivity, and lipid metabolism. The developmental logic is that infants who experience early growth restriction and then rapid postnatal weight gain may accumulate visceral adipose tissue preferentially, a pattern that is strongly associated with insulin resistance and dyslipidemia. The finding that infant BMI and weight trajectories are linked to three distinct cardiometabolic outcomes suggests that the first two years of life represent a critical period for metabolic programming, one that may be as consequential as the intrauterine environment itself.

The analysis also examined breastfeeding and found limited evidence suggesting a possible inverse association between breastfeeding and cardiometabolic risk in childhood and adolescence, though the authors characterized this evidence as limited and inconclusive because it was based on few studies per outcome. This finding is important because breastfeeding is a modifiable exposure with enormous public health implications. Human milk contains bioactive compounds, including long-chain polyunsaturated fatty acids, hormones, and growth factors, that could theoretically influence metabolic development. Breastfed infants also tend to have different growth trajectories than formula-fed infants, with slower early weight gain that may reduce the risk of later adiposity. However, the observational nature of the evidence means that confounding by socioeconomic status, maternal education, and other factors cannot be excluded, and the authors were appropriately cautious in their interpretation, noting that the evidence was limited and inconclusive rather than definitive.

The authors emphasize that their findings may support closer cardiometabolic monitoring of children with relevant early-life exposures and may inform future prevention research. This is a significant shift in clinical thinking. Traditionally, cardiometabolic risk assessment has been reserved for adults with established risk factors, but this meta-analysis suggests that children and adolescents with specific developmental exposures, such as maternal gestational diabetes, maternal obesity during pregnancy, or being born small or large for gestational age, may warrant earlier surveillance. The identification of modifiable early-life risk factors also opens the door to targeted interventions during pregnancy and infancy that could reduce the burden of cardiometabolic disease in future generations. The research was conducted by an expert group of the European branch of the International Life Sciences Institute and coordinated by the Early Nutrition and Long-term Health Task Force, with the scientific work carried out solely by the authors and ILSI Europe having no role in the definition of research questions, study design, data collection, statistical analysis, interpretation of results, or approval of the submitted manuscript.

The implications of this meta-analysis extend far beyond the clinic and into public health policy. With gestational diabetes affecting a growing proportion of pregnancies worldwide, and maternal obesity reaching epidemic levels, the developmental exposures identified in this study are becoming increasingly common. The finding that these exposures are associated with cardiometabolic outcomes in childhood and adolescence, rather than only in adulthood, suggests that the window for prevention may need to shift earlier. The authors’ rigorous methodology, including the correction for overlapping cohorts and the conservative classification of sparse evidence, provides a model for how future reviews in this field should be conducted. As the global burden of type 2 diabetes and cardiovascular disease continues to rise, understanding the developmental origins of these conditions has never been more urgent, and this meta-analysis represents a major step forward in that effort, offering a comprehensive map of the early-life risk factors that shape cardiometabolic health across the lifespan.

Subject of Research: Early-life risk factors and cardiometabolic outcomes in children and adolescents: a systematic review and meta-analysis

Article Title: Early-life risk factors and cardiometabolic outcomes in children and adolescents: a systematic review and meta-analysis

Article References: Brandimonte-Hernández, M., Ruiz-Ojeda, F. J., Blaauwendraad, S. M., Kamphuis, A. S., Flores-Ventura, E., Abrahamse-Berkeveld, M., Collado, M. C., van Diepen, J. A., Iozzo, P., Knipping, K., van Loo-Bouwman, C. A., Gaillard, R., & Gil, Á. (2026). Early-life risk factors and cardiometabolic outcomes in children and adolescents: a systematic review and meta-analysis. BMC Medicine. https://doi.org/10.1186/s12916-026-05316-7

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05316-7

Keywords: gestational diabetes, glucose intolerance, cardiometabolic risk, early-life risk factors, meta-analysis, BMC Medicine, pediatrics, developmental origins, maternal BMI, hypertension, Early-life, risk

Researchers analyzed data from a large cohort of patients with hypertension to examine the association between plasma aldosterone levels and the risk of cardiovascular disease.

The study found that higher aldosterone levels were associated with an increased risk of cardiovascular disease, and the relationship followed a nonlinear dose-response pattern.

These findings suggest that aldosterone may be a useful marker for identifying patients with hypertension at higher cardiometabolic risk.

The study drew on a retrospective cohort of 7,677 hospitalized patients with hypertension who were free of cardiometabolic multimorbidity at baseline, recruited between January 2010 and January 2026 at a specialized hypertension center in Xinjiang, China. Over an average follow-up of 3.52 years, 1,949 participants developed cardiometabolic multimorbidity, defined in this context as the coexistence of at least two major cardiometabolic disorders such as coronary heart disease, stroke, or type 2 diabetes. This large sample size and multi-year observation window allowed the investigators to model the exposure–outcome relationship with considerable statistical precision, including the shape of the dose–response curve rather than assuming a simple linear trend.

The central quantitative finding was that each 1-ng/dL increment in plasma aldosterone concentration corresponded to a 2% higher hazard of incident cardiometabolic multimorbidity after multivariable adjustment. When participants were grouped into quartiles of baseline aldosterone, the risk climbed steadily across categories: compared with the lowest quartile, the adjusted hazard ratios were 1.19 for the second quartile, 1.32 for the third, and 1.65 for the highest, with a highly significant trend across quartiles. Kaplan–Meier curves reinforced this gradient, showing that participants in the top aldosterone quartile accumulated incident multimorbidity at a visibly faster rate than those in the lower three quartiles throughout follow-up.

Restricted cubic spline analysis added an important nuance: the association was not strictly linear. The fitted curve identified an estimated inflection point at approximately 15.34 ng/dL, below which the relationship between aldosterone and multimorbidity risk was relatively flat, and above which the risk curve rose appreciably. This kind of threshold-like behavior is clinically meaningful because it suggests that modest variation in aldosterone within the lower part of the distribution may carry little prognostic consequence, whereas concentrations beyond the inflection point mark a segment of the hypertensive population in which risk escalates more steeply. The nonlinearity was statistically robust, with a P value for nonlinearity below 0.001.

A second layer of complexity emerged from subgroup analyses, which indicated that the strength of the aldosterone–multimorbidity association differed according to serum potassium status, with a statistically significant interaction. To probe this further, the researchers performed restricted cubic spline analyses stratified by potassium level and fitted a bivariate penalized spline model to characterize the joint nonlinear associations of serum potassium and aldosterone with multimorbidity risk. This approach reflects the tight physiological coupling between aldosterone and potassium homeostasis: aldosterone promotes renal potassium excretion, so circulating potassium may modify, or serve as a marker of, the downstream tissue effects of aldosterone excess. The observed interaction implies that a given aldosterone concentration may not carry the same prognostic weight in a hypokalemic patient as in one with normal or high potassium, a consideration that could matter when aldosterone-based stratification is eventually translated into practice.

Beyond association, the study tested whether aldosterone adds genuine predictive value to conventional risk assessment. Using time-dependent receiver operating characteristic analysis with inverse probability of censoring weighting—a technique that accounts for censored observations when evaluating discrimination over time—the investigators found that adding plasma aldosterone to a baseline prediction model raised the area under the curve for 3-year risk from 0.678 to 0.735, a statistically significant improvement. Reclassification metrics told a similar story: the survival-based net reclassification improvement was 0.372, and the integrated discrimination improvement was 0.038, both statistically significant. Calibration assessment and decision curve analysis extended the evaluation, with the latter suggesting that a model incorporating aldosterone would yield greater estimated net benefit than the conventional model across a range of clinically relevant threshold probabilities. In parallel, the Boruta algorithm, a wrapper-based feature selection method built on random forests, independently identified plasma aldosterone as an important predictor among the variables considered, providing a machine-learning perspective that complemented the regression-based findings.

The biological rationale for these observations rests on the expanding view of aldosterone as more than a regulator of sodium and water balance. As the terminal effector of the renin–angiotensin–aldosterone system, aldosterone acts on mineralocorticoid receptors in the kidney, vasculature, heart, and other tissues. Experimental and clinical work has linked aldosterone excess to endothelial dysfunction, oxidative stress, inflammation, and myocardial fibrosis through both mineralocorticoid receptor–dependent and receptor-independent pathways. These mechanisms plausibly connect aldosterone to the individual components of cardiometabolic multimorbidity—atherosclerotic vascular disease, cerebrovascular events, and disturbances of glucose and lipid metabolism—and may explain why elevated aldosterone would promote the co-occurrence of several such conditions in the same patient.

Importantly, the adverse associations observed in this cohort were not confined to patients with overt aldosterone excess. Primary aldosteronism, the classic syndrome of autonomous aldosterone production, is well established as a driver of disproportionately high rates of stroke, coronary heart disease, and heart failure. But prior studies in populations in which primary aldosteronism had been excluded have shown that higher aldosterone concentrations remain continuously associated with adverse cardiovascular outcomes even within the so-called normal range. The present findings extend that literature by focusing specifically on the transition from single-disease hypertension to cardiometabolic multimorbidity, a stage at which mortality risk rises above that of any single cardiometabolic condition alone.

Several methodological features strengthen the study’s internal validity. The multivariable Cox proportional hazards models adjusted for a panel of potential confounders, and the findings remained consistent across subgroup and sensitivity analyses, suggesting that the aldosterone association was not an artifact of a particular analytic choice or a vulnerable patient subgroup. The combination of classical epidemiological tools—Cox regression, Kaplan–Meier estimation, restricted cubic splines—with modern prediction metrics such as net reclassification improvement, integrated discrimination improvement, and decision curve analysis represents a fairly comprehensive appraisal of whether a biomarker is worth adding to existing risk models, addressing not only statistical association but also potential clinical utility.

Nevertheless, the retrospective design imposes limits on interpretation. Plasma aldosterone was measured at a single baseline time point in hospitalized patients, and single measurements may not capture long-term hormonal status, particularly given that aldosterone secretion varies with sodium intake, posture, circadian rhythm, and concurrent medications, including the antihypertensive agents themselves. Residual confounding by factors such as dietary patterns, adherence to therapy, and socioeconomic characteristics cannot be excluded in an observational cohort. The cohort was drawn from a single hypertension center in northwestern China, and the generalizability of the 15.34 ng/dL inflection point to other populations, laboratories, and assay platforms remains to be established, since aldosterone reference intervals can vary with measurement method. Reverse causation is another consideration: subclinical cardiometabolic disease may itself influence aldosterone regulation, although the exclusion of patients with prevalent multimorbidity at baseline and the consistent findings across sensitivity analyses partially mitigate this concern.

From a clinical standpoint, the study positions plasma aldosterone as a candidate for risk stratification among the large population of hypertensive patients who carry residual cardiovascular risk despite adequate blood pressure control. The improvement in the area under the curve from 0.678 to 0.735, while meaningful, indicates that aldosterone complements rather than replaces conventional predictors, and the decision curve results suggest that the added discrimination could translate into better-targeted preventive decisions at clinically relevant thresholds. The potassium-dependent modification of the association adds a practical dimension: any future use of aldosterone for stratification may need to be interpreted alongside serum potassium rather than in isolation.

Prospective validation in independent cohorts, ideally with repeated aldosterone measurements and diverse populations, would be the natural next step. Interventional questions also follow: if aldosterone marks a mechanistically relevant pathway rather than a passive correlate of risk, then mineralocorticoid receptor antagonism or other strategies that suppress aldosterone signaling might be tested for their ability to reduce the incidence of cardiometabolic multimorbidity in hypertensive patients with concentrations above the identified inflection point. Until such evidence accumulates, the study’s principal contribution is the demonstration that a routinely measurable hormone, long appreciated for its role in volume regulation, carries independent, nonlinear, and clinically quantifiable prognostic information about the burden of coexisting cardiometabolic disease in hypertension.

Subject of Research: Aldosterone levels may predict cardiometabolic risk in hypertension

Article Title: Dose–response association and predictive value of plasma aldosterone concentration for cardiometabolic multimorbidity in patients with hypertension: a retrospective cohort study

Article References: Zhang, Z., Li, N., Zhu, Q., Hu, J., Hong, J., Yang, W., Zhou, P., Ma, H., Ma, R., & Wu, T. (2026). Dose–response association and predictive value of plasma aldosterone concentration for cardiometabolic multimorbidity in patients with hypertension: a retrospective cohort study. Frontiers in Endocrinology, 17, Article 1965927. https://doi.org/10.3389/fendo.2026.1965927

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1965927

Keywords: aldosterone, hypertension, cardiovascular disease, cardiometabolic risk, cohort study, Dose, response, association, predictive, value, plasma, concentration

The research team enrolled 128 participants, dividing them into four groups: 30 normal-weight healthy controls with BMI between 18.5 and 23.9 kg/m², 31 overweight or obese individuals without diabetes whose BMI was 24.0 kg/m² or higher, 33 normal-weight patients with newly diagnosed T2DM, and 34 overweight or obese patients with T2DM. All participants underwent comprehensive echocardiographic assessment, including conventional ultrasound measurements and advanced 2D-STI analysis of right ventricular free wall strain, early diastolic strain rate (SRe), and late diastolic strain rate (SRa).

Right ventricular function was evaluated through multiple complementary parameters. The researchers measured right ventricular free wall global longitudinal strain (RVFWS), tricuspid annular plane systolic excursion (TAPSE), right ventricular fractional area change (FAC), and the SRe/SRa ratio, which reflects the balance between early and late diastolic relaxation of the right ventricle. They also assessed the myocardial performance index (MPI) and right ventricular outflow tract Doppler velocities to capture a complete picture of right-sided cardiac performance.

The results revealed a clear stepwise pattern of right ventricular deterioration across the four groups. Normal-weight healthy controls showed the best right ventricular performance, while overweight or obese individuals without diabetes already displayed measurable impairment in RVFWS and diastolic strain rates compared with their lean counterparts. Patients with normal-weight T2DM showed further declines, and those who carried both excess weight and diabetes exhibited the most severe right ventricular dysfunction of all four groups, with the lowest RVFWS values and the most abnormal SRe/SRa ratios.

Statistical analysis confirmed that both BMI and T2DM status independently contributed to right ventricular impairment, and that the combination produced a more pronounced effect than either factor alone. Two-way analysis of variance demonstrated significant main effects of BMI and diabetes on RVFWS, SRe, SRa, and the SRe/SRa ratio, along with a significant interaction between the two factors for several parameters. This interaction suggests that obesity and diabetes do not merely add their separate harms to the right ventricle but may amplify each other’s damaging influence through overlapping metabolic and inflammatory pathways.

Multiple linear regression analysis strengthened the case for BMI as a key driver of right ventricular damage. After adjusting for age, sex, heart rate, blood pressure, and glycemic control, BMI remained an independent predictor of reduced RVFWS and abnormal diastolic strain rates in the combined patient population. The findings indicate that every additional unit of BMI carries a measurable cost for right ventricular mechanics, even in people whose diabetes is newly diagnosed and not yet complicated by advanced cardiovascular disease.

The study also explored whether conventional echocardiographic parameters could detect the same pattern of right ventricular dysfunction. While TAPSE and FAC showed some differences between groups, these traditional measures were less sensitive than 2D-STI strain parameters in distinguishing early subclinical changes. This observation underscores the value of speckle tracking technology, which tracks the movement of individual speckles within the myocardial tissue frame by frame, providing a more nuanced assessment of regional cardiac deformation than visual estimation or single-plane measurements.

Mechanistically, the researchers propose several pathways through which excess adiposity and hyperglycemia converge to injure the right ventricle. Increased visceral fat promotes chronic systemic inflammation, elevates circulating free fatty acids, and fosters insulin resistance, all of which can impair cardiomyocyte metabolism and promote myocardial fibrosis. At the same time, chronic hyperglycemia accelerates the formation of advanced glycation end products, increases oxidative stress, and disrupts calcium handling within cardiac cells. The right ventricle, with its thinner walls and greater dependence on subendocardial blood supply, may be particularly vulnerable to these combined metabolic insults.

The clinical implications of the study are significant for the millions of people worldwide living with both obesity and diabetes. Right ventricular dysfunction is increasingly recognized as a predictor of adverse outcomes in heart failure, pulmonary hypertension, and other cardiovascular conditions, yet it often goes undetected until the disease is advanced. The findings suggest that 2D-STI could serve as a practical screening tool to identify patients at risk of early right ventricular damage, allowing clinicians to intervene earlier with weight management, glycemic control, and other cardioprotective strategies before irreversible structural changes take hold.

The authors acknowledge several limitations of their work, including its cross-sectional design, which cannot establish causality or track how right ventricular function evolves over time. The study also focused on newly diagnosed patients without established cardiovascular complications, so the findings may not generalize to those with long-standing diabetes or advanced heart disease. Nevertheless, the research adds compelling evidence that the right ventricle deserves closer attention in metabolic disease, and that the combination of elevated BMI and T2DM represents a particularly potent threat to this underappreciated cardiac chamber. Future longitudinal studies using serial speckle tracking assessments could clarify how quickly right ventricular function declines with ongoing metabolic exposure and whether early interventions can preserve or restore normal cardiac mechanics.

Subject of Research: Right ventricular function in type 2 diabetes and obesity

Article Title: Assessment of the impact of body mass index on right ventricular systolic and diastolic function in patients with type 2 diabetes mellitus using two-dimensional speckle tracking imaging

Article References: Wang, W., Peng, Y., Zhao, K., Zheng, Z., Feng, J., Zou, C., Sun, Y., Lin, B., Wang, L., Hu, B., & Yang, S. (2026). Assessment of the impact of body mass index on right ventricular systolic and diastolic function in patients with type 2 diabetes mellitus using two-dimensional speckle tracking imaging. Frontiers in Clinical Diabetes and Healthcare, 7, Article 1694955. https://doi.org/10.3389/fcdhc.2026.1694955

Image Credits: AI Generated

DOI: 10.3389/fcdhc.2026.1694955

Keywords: type 2 diabetes, obesity, right ventricle, speckle tracking, echocardiography, cardiac strain, diastolic function, BMI, cardiometabolic risk, subclinical dysfunction, Assessment, impact

The case for reframing rests on a growing body of evidence that neurotrauma does not simply heal and fade. Survivors of TBI and SCI frequently develop cardiovascular, metabolic, endocrine, neurological, psychiatric and functional complications that can emerge or worsen long after acute treatment ends. The paper’s authors, including co-first author Sandro Marini, MD, and co-senior and corresponding author Saef Izzy, MD, both of the Mass General Brigham Neuroscience Institute, describe mechanisms such as chronic inflammation, accelerated biological aging and elevated cardiometabolic risk as hallmarks of the post-injury state. These are not incidental consequences but, in the authors’ framing, core features of a chronic disease process — comparable in kind, if not in origin, to the systemic changes seen after stroke or in diabetes.

Much of the quantitative foundation for this argument comes from a sustained research program at Mass General Brigham. Over the past seven years, studies led by Izzy, Marini and colleagues — including large cohort analyses published in JAMA Network Open in 2022, 2024, August 2025 and November 2025 — documented that survivors of traumatic brain and spinal cord injury face measurably higher rates of new cardiovascular, endocrine, neurological and psychiatric conditions compared with the general population. Those studies helped establish the size and breadth of the long-term risk. The new Lancet Neurology paper represents a deliberate next step: translating an accumulating evidence base into an actionable model of care that health systems, payers and policymakers can actually implement.

To build that blueprint, the authors conducted a structured synthesis of the recent literature. They searched multiple databases for English-language studies published between 2020 and 2026, prioritizing prospective analyses of long-term outcomes after TBI or SCI, and consulted international experts and stakeholders across disciplines. They then integrated this evidence with established chronic-care models — those developed for stroke, diabetes and cancer survivorship — to design a practical pathway for long-term neurotrauma care. The methodological choice is significant: rather than inventing a new care paradigm from scratch, the team adapted frameworks already proven in other chronic disease contexts, arguing that neurotrauma deserves the same continuity, coordination and surveillance those fields now take for granted.

What the evidence consistently shows, according to the authors, is a stark mismatch between the biology of neurotrauma and the structure of health care delivery. While the injury initiates persistent biological and psychosocial changes, most health systems continue to provide episodic support rather than coordinated long-term follow-up. Surveillance is often fragmented or absent once patients leave acute care and rehabilitation, meaning complications may go unrecognized until they trigger hospitalization, functional decline or other preventable harm. In other words, the window in which early intervention could prevent secondary conditions is frequently missed — not because effective measures do not exist, but because no one is systematically watching for the warning signs.

The proposed solution is a prevention-first care pathway built around several concrete components. The authors envision neurotrauma care navigators — dedicated points of contact who help survivors recognize early warning signs, understand the purpose of recommended screenings and take an active role in their own preventive health. The pathway also includes scheduled multisystem screenings targeting cardiovascular, endocrine, neurological and psychiatric risk, telehealth-enabled care to extend reach beyond specialty centers, and direct connections to specialized services. For patients and families, the central message is that recovery and medical risk do not end at discharge, and that structured follow-up with clear information about long-term risks could convert a period of silent vulnerability into one of managed prevention.

Recognizing that health systems differ enormously in resources, the framework is deliberately tiered. At its base sits a core package deliverable with limited resources: a minimum dataset, community health workers, mobile health tools and teleconsultation can provide a practical starting point in lower-resource settings. At the top tier, patients with complex needs receive intensive multidisciplinary care. The design philosophy is that every health system can begin with what it has, rather than waiting for ideal infrastructure. This tiering also addresses a persistent equity problem, since survivors in rural areas and low-income countries currently face the greatest barriers to any follow-up care at all.

Beyond the clinical pathway, the paper identifies seven priorities for implementation spanning three domains. On the health policy front, the authors call for formal recognition of chronic neurotrauma, payment reform to reimburse longitudinal care, and the creation of longitudinal registries to track outcomes at scale. In clinical care, they emphasize access to specialized rehabilitation and closer integration with existing services for stroke, memory disorders, psychiatric illness and epilepsy — specialties that already possess the tools to manage many post-neurotrauma complications. The third domain covers workforce development and equity, along with building the economic evidence base needed to sustain these changes. The inclusion of economic analysis reflects a pragmatic recognition that even compelling clinical evidence fails to change systems without a financial case.

The authorship itself signals the breadth of the effort. In addition to Marini and Izzy, Mass General Brigham authors include Joseph Giacino, and the broader author list spans specialists in neurosurgery, rehabilitation medicine, neuropsychology, epidemiology and policy from institutions worldwide, together with the Global Coalition for TBI as a Notifiable and Chronic Condition. The paper is framed as a Policy View rather than a primary research article, a format designed to influence clinical guidelines, payer decisions and public health policy. Funding disclosures note grant support to Izzy from the National Institutes of Health and the Department of War, and the published disclosure statement covers royalties and institutional support among co-authors.

The team’s agenda now moves from advocacy to validation. The next step, the authors report, is to characterize people living with TBI more precisely by combining longitudinal clinical information with multiomic data — genomic, proteomic and other molecular profiles measured over time. That work should clarify why some individuals develop particular long-term complications while others do not, and allow the identification of distinct risk profiles. Those profiles would then be used to tailor prevention more effectively and to prospectively test the care pathways and interventions proposed in the paper. If successful, the shift the authors envision would mark one of the more consequential reframings in modern neurotrauma care: treating the aftermath of a blow to the brain or spinal cord not as a closed chapter, but as the beginning of a chronic condition that medicine can monitor, anticipate and, increasingly, prevent.

Subject of Research: Long-term multisystem complications and integrated chronic care models after traumatic brain and spinal cord injury

Article Title: Research Spotlight: Working towards an integrated, long-term approach for traumatic brain and spinal cord injury

Article References: Research Spotlight: Working towards an integrated, long-term approach for traumatic brain and spinal cord injury. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: traumatic brain injury, spinal cord injury, chronic disease, neurotrauma, long-term care, cardiometabolic risk, care navigation, telehealth, health policy, rehabilitation, The Lancet Neurology, Mass General Brigham